{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:18:55Z","timestamp":1793992735878,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,4]]},"DOI":"10.7759\/cureus.32174","type":"journal-article","created":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T08:50:44Z","timestamp":1670143844000},"source":"Crossref","is-referenced-by-count":9,"title":["Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Yukiko","family":"Otsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in\u00a0non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis F","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in\u00a0non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019, 19:495-509. 10.1038\/s41568-019-0179-8","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon K","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH, et al.. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012, 30:863-70. 10.1200\/JCO.2011.35.6345","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon A","year":"2022","unstructured":"Drilon A, Chiu CH, Fan Y, et al.. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC. JTO Clin Res Rep. 2022, 3:100332. 10.1016\/j.jtocrr.2022.100332","journal-title":"JTO Clin Res Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany S","year":"2021","unstructured":"Waliany S, Zhu H, Wakelee H, et al.. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021, 16:2029-39. 10.1016\/j.jtho.2021.07.030","journal-title":"J Thorac Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of\u00a0Cardiovascular Imaging","volume":"17","author":"Nagueh SF","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, et al.. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of\u00a0Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016, 17:1321-60. 10.1093\/ehjci\/jew082","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon A","year":"2020","unstructured":"Drilon A, Siena S, Dziadziuszko R, et al.. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21:261-70. 10.1016\/S1470-2045(19)30690-4","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112974","article-title":"Entrectinib, a new multi-target inhibitor for cancer therapy","volume":"150","author":"Jiang Q","year":"2022","unstructured":"Jiang Q, Li M, Li H, Chen L. Entrectinib, a new multi-target inhibitor for cancer therapy. Biomed Pharmacother. 2022, 150:112974. 10.1016\/j.biopha.2022.112974","journal-title":"Biomed Pharmacother"},{"key":"ref9","unstructured":"FDA. Highlights of prescribing information. (2019). Accessed: November 11, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243946","article-title":"Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer","volume":"14","author":"Fonseca M","year":"2021","unstructured":"Fonseca M, Chen DH, Walker JM, Ghosh AK. Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer. BMJ Case Rep. 2021, 14:e243946. 10.1136\/bcr-2021-243946","journal-title":"BMJ Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115635-entrectinib-induced-heart-failure-in-a-patient-with-metastatic-lung-adenocarcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:00Z","timestamp":1707508260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115635-entrectinib-induced-heart-failure-in-a-patient-with-metastatic-lung-adenocarcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.32174","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,4]]}}}